Hif-Phi for Management of Anaemia of Chronic Kidney Disease: An Overview

Anaemia is a common consequence of chronic renal disease, which affects 10% of the global population. The primary cause of it is the kidneys' diminished capacity to produce enough EPO in response to hypoxia or anemia. The management of anemia and quality of life have improved with the use of ESAs and iron therapy in current treatment. This treatment raises safety concerns as it attempts to bring the hemoglobin level close to normal. HIF-PHIs, or hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors, were created as a substitute method and oral treatment for anemia in chronic kidney disease in order to address these issues. Clinical trial data demonstrated no inferiority in correcting anemia when compared to ESAs or a placebo. Improved iron mobilization and utilization, a reduction in LDL cholesterol, and a reduction in major cardiovascular events were among the other benefits for inflammatory patients.